Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2021 | Early rescue intervention and detection of treatment failure in myeloma

Bruno Paiva • 28 May 2021
EHA 2021
Multiple Myeloma

Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, talks on the potential of developing a new treatment framework utilizing novel treatments and tools, in particular in relation to progressive disease and the improvement of early detection and intervention. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Bruno Paiva

MRD assessment as an early endpoint of treatment efficacy in AML: a PETHEMA registry study
2:22
MRD assessment as an early endpoint of treatment efficacy in AML: a PETHEMA registry study
Bruno Paiva • 6 Dec 2025
Combined assessment of CTCs and MRD for dynamic risk assessment of patients with multiple myeloma
2:25
Combined assessment of CTCs and MRD for dynamic risk assessment of patients with multiple myeloma
Bruno Paiva • 6 Dec 2025
Comprehensive genomic characterization of CTCs in multiple myeloma
1:38
Comprehensive genomic characterization of CTCs in multiple myeloma
Bruno Paiva • 6 Dec 2025
What is the most effective method for detecting circulating tumor cells in multiple myeloma?
1:40
What is the most effective method for detecting circulating tumor cells in multiple myeloma?
Bruno Paiva • 18 Sep 2025

Related Videos

Impact of race and social deprivation on clinical outcomes in newly diagnosed multiple myeloma
2:53
Impact of race and social deprivation on clinical outcomes in newly diagnosed multiple myeloma
Bruno Paiva • 7 Dec 2025
A novel remote monitoring system to support outpatient administration of bispecific T-cell engagers
2:35
A novel remote monitoring system to support outpatient administration of bispecific T-cell engagers
Bruno Paiva • 15 Dec 2025
The impact of functionally high-risk disease in patients with R/R myeloma receiving late-line CAR-T
2:15
The impact of functionally high-risk disease in patients with R/R myeloma receiving late-line CAR-T
Bruno Paiva • 7 Dec 2025
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Bruno Paiva • 18 Dec 2025
The content of VJHemOnc is intended for healthcare professionals